Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Aaron Wolfson
- Target Recruit Count
- 18
- Registration Number
- NCT05603910
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT
- Conditions
- Interventions
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Sun Yat-sen University
- Registration Number
- NCT05592197
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 59
- Registration Number
- NCT05585580
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
🇨🇳Qingdao Municipal Hospital（Group）, Qingdao, Shandong, China
🇨🇳Yantai Yuhuangding Hospital, Yantai, Shandong, China
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Wen Li
- Target Recruit Count
- 60
- Registration Number
- NCT05582278
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Melanoma Institute Australia
- Registration Number
- NCT05545969
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Wan-Guang Zhang
- Target Recruit Count
- 30
- Registration Number
- NCT05533892
- Locations
- 🇨🇳
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
- Conditions
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 112
- Registration Number
- NCT05523323
- Locations
- 🇨🇳
Shanghai East Hospital ( Site 3300), Shanghai, Shanghai, China
🇨🇳Henan Cancer Hospital ( Site 3309), Zhengzhou, Henan, China
🇨🇳Chongqing Cancer Hospital ( Site 3327), Chongqing, Chongqing, China
Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 46
- Registration Number
- NCT05509478
- Locations
- 🇨🇳
Liu Bo, Changchun, Jilin, China
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 274
- Registration Number
- NCT05444478
- Locations
- 🇨🇳
Hunan Provincial People's Hospital, Changsha, Hunan, China
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Universität des Saarlandes
- Target Recruit Count
- 50
- Registration Number
- NCT05433116
- Locations
- 🇩🇪
University Hospital Ulm, Otolaryngology & Head and Neck Surgery, Ulm, Baden-Württemberg, Germany
🇩🇪University Hospital Düsseldorf, Radiation Oncology, Düsseldorf, Northrhine-Westphalia, Germany
🇩🇪University Hospital Frankfurt/M, Center for Radiology, Frankfurt, Hesse, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.